论文部分内容阅读
目的 :了解帕尼培南 倍他米隆对临床常见致病菌的体外抗菌活性及治疗肺部感染的有效性及安全性。方法 :采用琼脂二倍稀释法测定帕尼培南 倍他米隆对 2 4 7株临床分离菌的MIC ,检测其对部分菌株的最低杀菌浓度 ;2 0例肺部感染病人使用帕尼培南 倍他米隆 5 0 0 /5 0 0mg ,q 12h ,iv ,gtt ,疗程3～ 7d。结果 :帕尼培南 倍他米隆与帕尼培南的体外抗菌活性基本一致 ,MIC50 ≤ 0 .0 0 75mg·L- 1,MIC90 为 0 .0 0 75～ 2mg·L- 1;对流感嗜血杆菌的MIC范围为 <0 .0 0 75～ 0 .12 5mg·L- 1;对阴沟肠杆菌、变形肠杆菌、铜绿假单孢菌的MIC50 和MIC90 分别为 0 .12 5和 0 .5 ,2和 4 ,4和 16mg·L- 1;帕尼培南 倍他米隆对金黄色葡萄球菌、表皮葡萄球菌、铜绿假单孢菌、肺炎克雷伯菌、大肠埃希菌、阴沟肠杆菌、变形肠杆菌及微球菌的最低杀菌浓度分别是其MIC的 1～ 8倍。致病菌阴转率为 77.8% ,治疗有效率为 75 % ,未出现明显不良反应。结论 :帕尼培南 倍他米隆对临床常见致病菌的体外抗菌活性强 ;对肺部感染有较好疗效 ,安全性好
OBJECTIVE: To understand the antibacterial activity of panipenem in the treatment of common pathogenic bacteria and the efficacy and safety of the treatment of pulmonary infection. Methods: The MICs of 247 clinical isolates of paniperidin betamemlon were determined by double dilution method of agar, and the minimum bactericidal concentration of some strains was tested. Twenty cases of pulmonary infection were treated with panipenem Betamelinone 500 / 500mg, q 12h, iv, gtt, treatment of 3 ~ 7d. Results: The in vitro antibacterial activity of panipenem-telbetanilone and panipenem was basically the same, the MIC50 was less than 0.0075 mg · L-1 and the MIC90 was 0.075-2 mg · L-1. MIC range of Haemophilus was <0.075 ~ 0.125mg · L-1; for Enterobacter cloacae, Enterobacter cloacae and Pseudomonas aeruginosa, MIC50 and MIC90 were 0.125 and 0.90, respectively. 5, 2 and 4, 4, and 16 mg · L -1, respectively. The effect of panipenem-telbetamil on Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Enterobacteriaceae, Enterobacter Enteritidis and Micrococcus minibacteria minimum bactericidal concentrations were 1 to 8 times its MIC. Pathogenic bacteria negative conversion rate of 77.8%, the effective rate of 75%, no significant adverse reactions. CONCLUSION: The antibacterial activity of panipenem-telbetamilone against common clinical pathogens in vitro is good. It has good curative effect on lung infection and good safety